KAHR
Developer of a cancer drug intended to activate immune responses by converting cancer camouflage into beacons for the immune system to attack. The company specializes in the multifunctional immuno-rec...
Valuation
$0
Share Price
N/A
Total Raised
$151.3M
Last Round
N/A